The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial

被引:11
作者
Dosani, M. [1 ,2 ]
Morris, W. J. [1 ,2 ]
Tyldesley, S. [1 ,2 ]
Pickles, T. [1 ,2 ]
机构
[1] BC Canc Agcy, Dept Radiat Oncol, Vancouver Ctr, Vancouver, BC, Canada
[2] Univ British Columbia, Div Radiat Oncol & Dev Radiotherapeut, Dept Surg, Vancouver, BC, Canada
关键词
Androgen deprivation therapy; brachytherapy; external beam radiotherapy; hot flashes; prostate cancer; testosterone recovery; QUALITY-OF-LIFE; DEPRIVATION THERAPY; SERUM TESTOSTERONE; LUTEINIZING-HORMONE; OLDER MEN; NORMALIZATION; CARCINOMA; TIME; RADIOTHERAPY; ABLATION;
D O I
10.1016/j.clon.2017.06.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: This study describes the proportion of men who experienced hot flashes (flashes), and the testosterone level at onset, peak frequency and cessation of flashes after 12 months of androgen deprivation therapy (ADT) in men undergoing curative-intent external beam radiation therapy (+/- brachytherapy boost). We also aimed to characterise testosterone recovery in this population. Materials and methods: This was a pre-specified secondary analysis of the ASCENDE-RT clinical trial. Three hundred and ninety-eight men were randomised. All received 12 months of ADT. The presence and frequency of flashes were patient reported. Cessation of flashes was defined as the first date a patient reported resolution of this symptom. Testosterone recovery was defined as any single serum testosterone above the threshold of 5, 7.5 or 10 nmol/l. Results: The median age and follow-up were 68 years and 6.1 years. Flashes were reported in 93% of men. Flashes began and reached peak frequency at a median time of 4.0 months from the first luteinizing hormone-releasing hormone injection when testosterone levels had fallen to castrate. The median time to cessation of flashes was 7.6 months after the cessation of ADT (last injection _ 3 months), when the median testosterone had risen to 5.7 nmol/l. A resolution of flashes was reported in 99% of patients. Baseline testosterone was available in 338 patients (85%). The median baseline testosterone was 13.2 nmol/l. The median (95% confidence interval) time of testosterone recovery to thresholds of 5 nmol/l, 7.5 nmol/l and 10 nmol/l were 9 (9-10) months, 13 (10-15) months and 18 (17-19) months from the cessation of ADT. At the time of censor, 96, 94 and 91% of patients had recovered testosterone to thresholds of 5, 7.5 and 10 nmol/l. Conclusion: Flashes occur at castrate levels of testosterone, with cessation of hot flashes antedating full recovery of testosterone in most patients. Rates of testosterone recovery after 12 months of ADT exceed 90%, although it can be delayed. (C) 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:696 / 701
页数:6
相关论文
共 24 条
[1]   Testosterone replacement therapy after primary treatment for prostate cancer [J].
Agarwal, PK ;
Oefelein, MG .
JOURNAL OF UROLOGY, 2005, 173 (02) :533-536
[2]  
Baum N, 2003, GERIAT AGING, V6, P43
[3]   INTERVAL TO TESTOSTERONE RECOVERY AFTER HORMONAL THERAPY FOR PROSTATE CANCER AND RISK OF DEATH [J].
D'Amico, Anthony V. ;
Chen, Ming-Hui ;
Renshaw, Andrew A. ;
Loffredo, Marian ;
Kantoff, Philip W. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01) :10-15
[4]   In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.: IJROBP 2002;52: 439-443 [J].
Dearnaley, DP ;
Norman, AR ;
Shahidi, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (03) :981-981
[5]   AGE, DISEASE, AND CHANGING SEX-HORMONE LEVELS IN MIDDLE-AGED MEN - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY [J].
GRAY, A ;
FELDMAN, HA ;
MCKINLAY, JB ;
LONGCOPE, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (05) :1016-1025
[6]   Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer [J].
Gulley, James L. ;
Aragon-Ching, Jeanny B. ;
Steinberg, Seth M. ;
Hussain, Maha H. ;
Sartor, Oliver ;
Higano, Celestia S. ;
Petrylak, Daniel P. ;
Chatta, Gurkamal S. ;
Arlen, Philip M. ;
Figg, William D. ;
Dahut, William L. .
JOURNAL OF UROLOGY, 2008, 180 (04) :1432-1437
[7]   A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy [J].
Gulley, JL ;
Figg, WD ;
Steinberg, SM ;
Carter, J ;
Hussain, MH ;
Dahut, WL .
JOURNAL OF UROLOGY, 2005, 173 (05) :1567-1571
[8]   Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity [J].
Higano, CS .
UROLOGY, 2003, 61 (2A) :32-38
[9]   Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial [J].
Irani, Jacques ;
Salomon, Laurent ;
Oba, Rostand ;
Bouchard, Philippe ;
Mottet, Nicolas .
LANCET ONCOLOGY, 2010, 11 (02) :147-154
[10]   Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer [J].
Kaku, H ;
Saika, T ;
Tsushima, T ;
Ebara, S ;
Senoh, T ;
Yamato, T ;
Nasu, Y ;
Kumon, H .
PROSTATE, 2006, 66 (04) :439-444